ARTICLE | Finance
Plus a $100M PIPE for cancer play Context Therapeutics
By Stephen Hansen, Director of Biopharma Intelligence
May 3, 2024 6:05 PM UTC
Two rare disease biotechs raised substantial capital to help finance regulatory and commercial preparations for late-stage programs.
Soleno Therapeutics Inc. (NASDAQ:SLNO) announced after market close on Thursday that it had raised $138 million through the sale of 3 million shares at $46 per share — a 7% discount to Thursday’s close of $49.23…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/652324/public-equity-report-soleno-abeona-raise-capital-for-late-stage-rare-disease-programs